Systemic treatment modalities for eradication of multiple therapy resistant genital warts are so far not available. In this study laser treated patients with multiple genital warts received postoperatively either interferon alpha-2b subcutaneously (s.c.) 5 x 10' IU or matching placebo three times weekly for four weeks. At the conclusion of the study, 6-8 weeks after discontinuation of therapy, a significantly higher cure rate was found in the group of interferon-treated patients (14 of 27 (52%) patients cured) than among placebo treated patients (5 of 22 (23%) patients cured) (p < 0-05). The side effects of fever, chills, myalgia, headache and leukopenia occurred more commonly in the interferon treated group than in the placebo group. However, only three of 32 patients discontinued interferon therapy because of side effects. We conclude that the addition of s.c. administered interferon alpha-2b to laser treated patients with chronic therapy resistant genital warts is fairly well tolerated and that it significantly enhances the chance ofeliminating the disease.
Introduction
The optimal treatment modality has not been established in patients with recalcitrant multiple genital warts. A variety of ablative treatments for podophyllin resistant genital warts are available, including cryosurgery, electrocautery and laser therapy.
Recently both recombinant alpha interferons and lymphoblastoid interferon intralesionally injected have shown to be effective in eradicating small numbers of warts."' Systemic administration of alpha interferons and lymphoblastoid interferon as monotherapy has also demonstrated an effect on human papillomavirus (HPV)-induced lesions," an effect that in one study was comparable to electrocautery. 6 The current therapy of choice for multiple chronic genital warts in Danish dermatologic departments is laser therapy, but it is our experience that the cure rate is disappointingly low for this group of patients. Placebo controlled trials combining laser therapy with systemic administration of alpha interferon in these patients has to our knowledge not been pub-
lished.
In this placebo controlled study we show that laser treated patients with otherwise therapy resistant genital warts have a higher cure rate, if the surgical procedure is followed by a course of subcutaneous (s.c.) interferon alpha-2b injections.
Patients and methods
The study was conducted, and approved by the local ethics committees, at the Dermato-Venereological centres in Copenhagen, Aarhus and Odense and at one gynaecologic centre in Copenhagen, which enrolled 14, 24, 10 and 7 patients, respectively. The patients were all referred for laser therapy and all had podophyllin resistant genital warts. Sixty-nine per cent of the study population had had warts for more than 12 months. The majority of the patients had previously been treated with electrocautery, cryotherapy or laser ( Analysis of the demographics of the two groups indicated no significant differences with respect to any variable (table 1) .
The maximal differences in clinical response between the interferon and the placebo groups occurred 6 and 8 weeks after completion of the injection therapy (table 2). At that time 14 of 27 interferon recipients (52%) and five of 22 placebo recipients (23%) had no detectable warts at the clinical examination (p < 0-05). Of the 14 patients who had received interferon and were followed after the study period, two had a relapse and 10 patients were free of warts after 24 weeks of follow-up. Two of the 14 patients were lost to follow-up.
The response to interferon appeared to be independent of the sex of the patient, previous therapy, wart age and location of warts. However, interferon responders had compared with non- Analysis of blood samples obtained during therapy revealed abnormalities in white-cell and platelet counts. Nine patients, who received interferon, had leukopenia; six had white-cell counts of 3-2 to 3.9 x 103/mm3, whereas three had counts of 2 1 to 2-9 x 103/mm3. Thrombocytopenia was noted in one interferon treated patient (126,000 cells/mm3). These abnormal values all returned to normal at the end of the study. None of the treated patients had abnormal liver-function tests. Two patients had one injection postponed for 3 days due to leukopenia.
Discussion
As compared with placebo recipients interferon alpha-2b recipients were shown to obtain a significantly increased cure rate 6 and 8 weeks after conclusion of 4 weeks of therapy. The therapeutic response was sustained as 71 and possibly as high as 86% of the interferon responders were still free of warts at the 24 week follow-up. Patients with 11 or more warts responded less favourably than patients with 10 or less warts. This is in full accordance with the results reported in a previous investigation of intralesionally injected interferon alpha-2b, where patients with small wart areas responded more readily than patients with large wart areas.'
We do not know the optimal duration of the interferon therapy postoperatively. It is possible, however, that a more prolonged injection period would result in an even higher cure rate in analogy with the experience in patients with chronic active hepatitis B where s.c. injections of interferon alpha2b 5 x 10' I.U. three times weekly for 16 weeks are needed for elimination of the chronic infection in a significant proportion of the patients.7 Future doseresponse studies should evaluate this aspect.
The cure rate of 23% obtained in the placebo group was nearly identical to the 27% cure rate seen in Danish patients with chronic genital warts treated with CO,-laser.8
The beneficial effect of interferon demonstrated in our study is supported by the finding, in a recently published uncontrolled study9 that adjuvant systemic interferon alpha-2b (3 x 106 I.U. daily for 7 days) given to laser treated patients with refractory genital warts resulted in a high cure rate.
Owing to the multiple and discrete distribution of the warts, we have not performed a quantitative assessment of the total wart area before and after therapy. This approach has been used in studies evaluating the efficacy of intralesionally injected interferon alpha-2b into 1 to 3 warts,'°but although this would be optimal, practical reasons did not allow this procedure in our study. Treatment modalities using intralesional or perilesional injection of interferon is in our opinion not a feasible way of treatment in patients with multiple disseminated lesions.
Systemic adverse reactions to interferon including fever, chills, headache, myalgia, and fatigue were usually mild and decreased in intensity during the four week treatment period suggesting that a tolerance to treatment developed. All side effects, including the decrease in white cell and platelet counts, are commonly associated with systemic interferon therapy.
The results of the present study indicate that a sufficiently high concentration of interferon is obtained in the HPV infected genital epithelium, and we consider the systemic administration ofinterferon alpha-2b to be a suitable way of potentiating the effect of laser therapy in otherwise therapy resistant patients.
